These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Blake S; Hughes TP; Mayrhofer G; Lyons AB Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113 [TBL] [Abstract][Full Text] [Related]
4. Subcellular distribution of Lck during CD4 T-cell maturation in the thymic medulla regulates the T-cell activation threshold. Stephen TL; Wilson BS; Laufer TM Proc Natl Acad Sci U S A; 2012 May; 109(19):7415-20. PubMed ID: 22529380 [TBL] [Abstract][Full Text] [Related]
6. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Leonard JT; Kosaka Y; Malla P; LaTocha D; Lamble A; Hayes-Lattin B; Byrd K; Druker BJ; Tyner JW; Chang BH; Lind E Blood; 2021 Feb; 137(7):939-944. PubMed ID: 32898857 [TBL] [Abstract][Full Text] [Related]
7. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Weichsel R; Dix C; Wooldridge L; Clement M; Fenton-May A; Sewell AK; Zezula J; Greiner E; Gostick E; Price DA; Einsele H; Seggewiss R Clin Cancer Res; 2008 Apr; 14(8):2484-91. PubMed ID: 18413841 [TBL] [Abstract][Full Text] [Related]
8. Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis. Wölfl M; Schwinn S; Yoo YE; Reß ML; Braun M; Chopra M; Schreiber SC; Ayala VI; Ohlen C; Eyrich M; Beilhack A; Schlegel PG Blood; 2013 Aug; 122(7):1203-13. PubMed ID: 23836556 [TBL] [Abstract][Full Text] [Related]
9. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro. Nerreter T; Distler E; Köchel C; Einsele H; Herr W; Seggewiss-Bernhardt R Exp Hematol; 2013 Jul; 41(7):604-614.e4. PubMed ID: 23466625 [TBL] [Abstract][Full Text] [Related]
10. Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner. Won J; Hur YG; Hur EM; Park SH; Kang MA; Choi Y; Park C; Lee KH; Yun Y Eur J Immunol; 2003 Apr; 33(4):870-9. PubMed ID: 12672052 [TBL] [Abstract][Full Text] [Related]
11. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Seggewiss R; Loré K; Greiner E; Magnusson MK; Price DA; Douek DC; Dunbar CE; Wiestner A Blood; 2005 Mar; 105(6):2473-9. PubMed ID: 15572591 [TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia. Harrington P; Dillon R; Radia D; Rousselot P; McLornan DP; Ong M; Green A; Verde A; Hussain F; Raj K; Kordasti S; Harrison C; De Lavallade H Haematologica; 2023 Jun; 108(6):1555-1566. PubMed ID: 36700403 [TBL] [Abstract][Full Text] [Related]
13. The EMT/ITK/TSK (EMT) tyrosine kinase is activated during TCR signaling: LCK is required for optimal activation of EMT. Gibson S; August A; Kawakami Y; Kawakami T; Dupont B; Mills GB J Immunol; 1996 Apr; 156(8):2716-22. PubMed ID: 8609388 [TBL] [Abstract][Full Text] [Related]
14. The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T-cell function. Wehrstedt S; Kubis J; Zimmermann A; Bruns H; Mayer D; Grieshober M; Stenger S Eur J Immunol; 2018 Nov; 48(11):1892-1903. PubMed ID: 30242834 [TBL] [Abstract][Full Text] [Related]
15. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. Appleman LJ; van Puijenbroek AA; Shu KM; Nadler LM; Boussiotis VA J Immunol; 2002 Mar; 168(6):2729-36. PubMed ID: 11884439 [TBL] [Abstract][Full Text] [Related]
17. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139 [TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. Chang AY; Wang M BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490 [TBL] [Abstract][Full Text] [Related]
19. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118 [TBL] [Abstract][Full Text] [Related]
20. Lck Inhibits Heat Shock Protein 65-Mediated Reverse Cholesterol Transport in T Cells. Luo T; Hu J; Xi D; Xiong H; He W; Liu J; Li M; Lu H; Zhao J; Lai W; Guo Z J Immunol; 2016 Nov; 197(10):3861-3870. PubMed ID: 27742830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]